Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and beta-thalassemia therapies.  Inherited blood disorders affect millions of people worldwide. As per NIH, Sickle cell disease affects around 70,000 to 80,000 Americans, whereas, Beta-thalassemia, globally affects almost 288,000 people, and is comparatively rare in … Continue reading GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3